Teva, Cephalon Get European Approval On Merger; Noven Files Patent Infringement Lawsuit against Watson. Print E-mail
By Staff and Wire Reports   
Thursday, 13 October 2011 17:50
Below is a look at some of the headlines for companies that made news in the healthcare sector on October 13, 2011.

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA)
said it received approval from the European Commission to proceed with its buyout of Cephalon, Inc.  (NASDAQ:CEPH).

As part of the process, Teva must divest Cephalon's right to market generic modafinil in France. The deal is expected to close Friday.

---

Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court of New Jersey against Watson Pharmaceuticals  (NYSE:WPI)  for infringement of certain Noven patents (the "Patents") by Watson.

The lawsuit was filed as a result of an Abbreviated New Drug Application (ANDA) submission by Watson seeking FDA approval to market and sell a generic version of Daytrana(R) (methylphenidate transdermal system) prior to the scheduled expiration of the Patents in 2018. The lawsuit reflects Noven's commitment to vigorously defending its intellectual property rights against infringement.

Under the Hatch-Waxman Act, because Noven filed this patent infringement lawsuit within 45 days of receiving a Paragraph IV notification letter from Watson, the FDA cannot approve Watson's ANDA for 30 months (until March 2014), unless the district court finds the Patents invalid or not infringed before the 30 months pass.


Also Thursday:



Accelr8 Technology Corporation (NYSE Amex: AXK) announced that upon reaching the end of its technology evaluation agreement with Novartis (Sep 30, 2011), discussion has now shifted to searching within Novartis for funding vehicles.

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes,announced that the reimbursement for its lead product for oral mucositis, MuGard, has increased significantly over the past few months.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in patients with Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib: Results of a Multicenter Phase 1/2 Trial" reporting Phase 1/2 combination activity of perifosine in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 10, 2011 online edition of the Journal of Clinical Oncology (JCO).

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL)
, a specialty biopharmaceutical company, today announced that the Company's low testosterone awareness campaign, Low T Facts, was recognized as the Best Interactive Initiative for Consumers at the 2011 Medical Marketing & Media (MM&M) Awards.

BioNeutral Group, Inc. (OTCBB: BONU), a specialty life science technology-based company, today announced that it has signed a distribution agreement with Hamilton Research LLC, an affiliate division of Hamilton Thorne Ltd. www.hamiltonthorne.com, to introduce, market and distribute its newly approved Ygiene®-206 Sterilant to the Veterinary industry.

BioTime, Inc. (NYSE Amex:BTX) announced today the publication in the peer-reviewed journal Stem Cell Research of the complete genome sequence analysis of five clinical-grade human embryonic stem cell lines.

Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that the initial product analyzing and production run has been completed and the commercial packaging process is now underway.

Cerus Corporation (NASDAQ:CERS) announced today that its third quarter 2011 financial results will be released on Tuesday, November 1, 2011, after the close of the stock market.

China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced details of its upcoming annual general meeting of stockholders (the "Annual Meeting").

China Sky One Medical, Inc. (NASDAQ: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it held its 2011 Annual Meeting of Stockholders (the ''Annual Meeting'') on October 12, 2011, in Harbin, PRC.

Codexis, Inc. (Nasdaq: CDXS) today announced the company will host a conference call and webcast on Tuesday, November 1, 2011 at 4:30 p.m. Eastern Time to discuss its third quarter 2011 financial results for the period ended September 30, 2011.   

CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that ValveXchange, Inc., a company in which CryoLife owns a minority interest, has completed the first three human implants with its novel Vitality™ two-part heart valve system.

Daxor Corporation (NYSE Amex: DXR)
, a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Schnitzler Cardiovascular Consultants PLLC (SCC).

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the launch of its latest formulation of MEDIHONEY®, the .5 ounce MEDIHONEY Gel, at the Fall 2011 Symposium on Advanced Wound Care (SAWC).

Galectin TherapeuticsInc. (OTC: GALT), the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins today announced that its abstract was accepted by the European Association for the Study of the Liver (EASL) for presentation at its Special Conference on Liver Transplantation to be held in Lisbon, Portugal, December 15-17, 2011.

Horizon Pharma, Inc. (NASDAQ: HZNP) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for Application Serial No. 12/324808 entitled "Stable Compositions of Famotidine and Ibuprofen" with claims that cover DUEXIS®.

InSite Vision Incorporated (OTCBB:INSV) today announced that Timothy Ruane, Chief Executive Officer of InSite Vision, will present a company update at 8:30 am ET at the Newsmakers in the Biotech Industry Conference being held at the Millennium Broadway Hotel and Conference Center in New York City on Friday, October 21, 2011.

ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) today announced top-line results from the second of its two Phase 3 studies to evaluate the short-term safety and efficacy of two concentrations of REMURA™ (bromfenac ophthalmic solution for dry eye) in alleviating the signs and symptoms of dry eye disease.

Marijuana, Inc. (PINKSHEETS: HEMP) is proud to announce the launch of the Eco-Harmony Loyalty Benefits and Rewards Card. After more than two years in development, at a cost of over $1.2 million dollars, The Eco-Harmony Loyalty Benefits and Rewards Card targets cultural creative merchants and consumers from a wide variety of industries, and is now in beta test at a high end retail boutique in the San Francisco Bay area. Aggressive marketing of the card will commence this quarter.

A Medco Health Solutions, Inc. (NYSE: MHS)
gene testing analysis found that 38 percent of patients prescribed Plavix® (clopidogrel)—an anti-platelet drug used to prevent blood clots, heart attack and stroke—were also using another drug that would impede its effectiveness.

Medtronic, Inc. (NYSE: MDT) today announced plans to introduce two of its next-generation cardiovascular devices in Japan, the world’s second largest market for advanced medical technology: the Integrity® Coronary Stent System for the treatment of narrowed heart arteries due to atherosclerosis and the Endurant® AAA Stent Graft System for the treatment of abdominal aortic aneurysms.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of new exploratory pre-specified analyses from the ongoing STARTMRK Phase III study of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy compared to efavirenz in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.

Micromet, Inc. (NASDAQ: MITI) today outlined a clinical development plan intended to support U.S. registration of its lead product candidate blinatumomab in patients with B-precursor relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL).

Modern Mobility Aids, Inc. (OTC BB: MDRM), headquartered in Nevada, USA, is adding Darshna Tanna to its Board of Directors. Ms. Tanna's appointment follows the recent announcement of Mr. Ferman Naqvi's, CA, appointment to the Board.

mPhase Technologies, Inc. (OTCBB: XDSL) reported today that it has been granted access to use the technical facilities at the Center for Nanoscale Materials (CNM), Argonne National Labs, Illinois, based on the acceptance of a technical proposal submitted for user-initiated nanoscience & nanotechnology research. mPhase plans on using the opportunity to conduct technical analysis and refinement of the smart surfaces technology developed by mPhase, using sophisticated laboratory tools not readily available to small businesses.

Nuvilex, Inc. (OTCQB:NVLX) announced its affiliate was invited to present at the recent BIO KOREA 2011 conference and exhibition held in Seoul, Korea. BIO KOREA is one of Asia's most important biotech events that included internationally renowned speakers and major pharmaceutical companies.

Optimer Pharmaceuticals (NASDAQ: OPTR) today announced that new research findings for DIFICID™ (fidaxomicin) tablets will be featured in presentations at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) occurring October 20-23 in Boston.

PharmAthene, Inc. (NYSE Amex: PIP) today announced that it has filed its legal brief in response to SIGA Technologies' motion for reargument.

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced it has entered into a definitive agreement with investors to purchase an aggregate of $1.9 million in securities in a private placement transaction.

Safeguard Scientifics, Inc. (NYSE: SFE)
, a holding company that builds value in growth-stage life sciences and technology companies, today announced that it will release its financial results for the third quarter ended September 30, 2011 prior to market open on Wednesday, October 26, 2011.

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the publication of a preclinical study demonstrating highly specific, functional correction of the alpha 1-antitrypsin (A1AT) gene defect in patient-derived induced pluripotent stem cells (iPSCs) using zinc finger nucleases (ZFNs).

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce third quarter 2011 earnings on Friday October 28, 2011.

Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the four manufacturers to supply seasonal influenza vaccine to the citizens of Beijing for the fourth time.

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the 2011 NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel and Conference Center in New York City on Friday, October 21, 2011 at 2:00 p.m. Eastern Time.

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at the BioCentury Newsmakers in the Biotech Industry Conferencein New York on October 21, 2011 at 11:00 a.m. ET.

ULURU Inc. (NYSE AMEX: ULU), announced today that it has signed a binding letter of intent with Melmed Holdings AG, a company based in Switzerland, to license Altrazeal® for the European Union.

Vanguard Health Systems, Inc. (NYSE: VHS) announced that Philip N. Bredesen has joined the Company's Board of Directors.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter